Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer
Roche’s pharma chief Bill Anderson is taking a victory lap before he steps down at the end of the year.
The FDA last week approved Roche’s blockbuster PD-L1 drug Tecentriq for adults and kids suffering an extremely rare soft tissue cancer, three weeks ahead of the initial goal date.
Alveolar soft part sarcoma (ASPS) — a type of soft tissue cancer that starts in connective tissues such as fat, muscles or nerves — is most commonly found in younger people, and often at an advanced stage, Roche’s Genentech announced last week. However, the disease can also spread slowly over decades. Only about 80 cases are diagnosed annually in the US.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters